Redeye interviews Mendus' CEO Erik Manting. We talk about the recently started clinical programme in CML and how vididencel is positioned relative to TERN-701, which was acquired recently at a record-high valuation. We also discuss the expanded AML programme, including the DIVA study.

Läs mer på Redeye

Ämnen i artikeln


Mendus

Senast

4,89

1 dag %

−2,10%

1 dag

1 mån

1 år

Marknadsöversikt

1 DAG %

Senast

1 mån